Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Study sponsor: Allarity Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-03Estimated
Enrollment · participants40Estimated
Source updated2025-08-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.